Staidson (Beijing) BioPharmaceuticals Co., Ltd. (300204.SZ)
CNY 7.86
(0.51%)
CNY 7.86
(0.51%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 665.62 Million CNY | -3.49% |
| 2022 | 670.46 Million CNY | -4.48% |
| 2021 | 701.91 Million CNY | 38.81% |
| 2020 | 505.68 Million CNY | -14.21% |
| 2019 | 589.45 Million CNY | -7.27% |
| 2018 | 635.65 Million CNY | -39.98% |
| 2017 | 1.05 Billion CNY | -1.09% |
| 2016 | 1.07 Billion CNY | 12.49% |
| 2015 | 951.85 Million CNY | 9.58% |
| 2014 | 868.63 Million CNY | 16.06% |
| 2013 | 748.41 Million CNY | 112.01% |
| 2012 | 353.01 Million CNY | 349.95% |
| 2011 | 78.45 Million CNY | 59.76% |
| 2010 | 49.11 Million CNY | 43.01% |
| 2009 | 34.33 Million CNY | 62.76% |
| 2008 | 21.09 Million CNY | 107.6% |
| 2007 | 10.16 Million CNY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 67.21 Million CNY | -18.56% |
| 2024 Q3 | 70.5 Million CNY | 3.13% |
| 2024 Q1 | 82.52 Million CNY | -67.84% |
| 2023 FY | 647.07 Million CNY | -3.49% |
| 2023 Q1 | 102.41 Million CNY | -49.29% |
| 2023 Q2 | 192.09 Million CNY | 87.57% |
| 2023 Q4 | 256.63 Million CNY | 123.04% |
| 2023 Q3 | 115.06 Million CNY | -40.1% |
| 2022 Q4 | 201.95 Million CNY | 10.08% |
| 2022 FY | 670.46 Million CNY | -4.48% |
| 2022 Q1 | 120.83 Million CNY | -44.55% |
| 2022 Q2 | 164.23 Million CNY | 35.92% |
| 2022 Q3 | 183.45 Million CNY | 11.7% |
| 2021 Q2 | 168.27 Million CNY | 40.89% |
| 2021 Q1 | 119.43 Million CNY | -27.67% |
| 2021 FY | 701.91 Million CNY | 38.81% |
| 2021 Q4 | 217.9 Million CNY | 11.0% |
| 2021 Q3 | 196.3 Million CNY | 16.66% |
| 2020 FY | 505.68 Million CNY | -14.21% |
| 2020 Q4 | 165.13 Million CNY | 21.61% |
| 2020 Q3 | 135.79 Million CNY | 3.93% |
| 2020 Q2 | 130.65 Million CNY | 76.34% |
| 2020 Q1 | 74.09 Million CNY | -51.73% |
| 2019 FY | 589.45 Million CNY | -7.27% |
| 2019 Q3 | 156.93 Million CNY | 4.55% |
| 2019 Q4 | 153.49 Million CNY | -2.19% |
| 2019 Q2 | 150.1 Million CNY | 16.44% |
| 2019 Q1 | 128.91 Million CNY | -17.91% |
| 2018 FY | 635.65 Million CNY | -39.98% |
| 2018 Q1 | 200.12 Million CNY | -20.0% |
| 2018 Q4 | 157.04 Million CNY | -1.22% |
| 2018 Q3 | 158.97 Million CNY | 33.02% |
| 2018 Q2 | 119.51 Million CNY | -40.28% |
| 2017 Q4 | 250.13 Million CNY | -7.84% |
| 2017 Q1 | 248.84 Million CNY | -22.76% |
| 2017 Q2 | 288.67 Million CNY | 16.01% |
| 2017 Q3 | 271.42 Million CNY | -5.97% |
| 2017 FY | 1.05 Billion CNY | -1.09% |
| 2016 FY | 1.07 Billion CNY | 12.49% |
| 2016 Q1 | 199.88 Million CNY | -29.3% |
| 2016 Q4 | 322.17 Million CNY | 10.69% |
| 2016 Q2 | 257.64 Million CNY | 28.9% |
| 2016 Q3 | 291.06 Million CNY | 12.97% |
| 2015 Q3 | 253.65 Million CNY | 1.74% |
| 2015 FY | 951.85 Million CNY | 9.58% |
| 2015 Q4 | 282.73 Million CNY | 11.46% |
| 2015 Q2 | 249.32 Million CNY | 50.07% |
| 2015 Q1 | 166.13 Million CNY | -29.74% |
| 2014 Q4 | 236.45 Million CNY | 11.78% |
| 2014 FY | 868.63 Million CNY | 16.06% |
| 2014 Q1 | 176.36 Million CNY | -30.01% |
| 2014 Q2 | 244.27 Million CNY | 38.51% |
| 2014 Q3 | 211.54 Million CNY | -13.4% |
| 2013 Q3 | 210.29 Million CNY | 29.95% |
| 2013 Q4 | 251.96 Million CNY | 19.81% |
| 2013 FY | 748.41 Million CNY | 112.01% |
| 2013 Q1 | 124.33 Million CNY | -26.31% |
| 2013 Q2 | 161.82 Million CNY | 30.15% |
| 2012 Q1 | 26.63 Million CNY | 20.47% |
| 2012 Q4 | 168.73 Million CNY | 40.48% |
| 2012 Q2 | 37.52 Million CNY | 40.86% |
| 2012 Q3 | 120.11 Million CNY | 220.13% |
| 2012 FY | 353.01 Million CNY | 349.95% |
| 2011 Q1 | 13.25 Million CNY | -20.83% |
| 2011 FY | 78.45 Million CNY | 59.76% |
| 2011 Q3 | 24.24 Million CNY | 28.67% |
| 2011 Q4 | 22.11 Million CNY | -8.8% |
| 2011 Q2 | 18.84 Million CNY | 42.16% |
| 2010 Q2 | 11.2 Million CNY | 30.2% |
| 2010 FY | 49.11 Million CNY | 43.01% |
| 2010 Q3 | 13.55 Million CNY | 21.0% |
| 2010 Q1 | 8.6 Million CNY | 0.0% |
| 2010 Q4 | 16.74 Million CNY | 23.53% |
| 2009 FY | 34.33 Million CNY | 62.76% |
| 2008 FY | 21.09 Million CNY | 107.6% |
| 2007 FY | 10.16 Million CNY | 0.0% |